Publications by authors named "Yosuke Okada"
Risk Stratification Using DIPSS and Splenomegaly in Myelofibrosis Treated with Pre-Transplant JAK inhibitors.
Transplant Cell Ther
September 2025
The Dynamic International Prognostic Scoring System for primary myelofibrosis (DIPSS) has been reported to predict transplant outcomes in myelofibrosis (MF) patients. Recently, the pre-transplant use of JAK inhibitors has become common in clinical practice, but it is unclear whether DIPSS is also useful for predicting transplant outcomes for these patients. In this study, we compared the prognostic impact of DIPSS between MF patients with and without pre-transplant Ruxolitinib therapy.
View Article and Find Full Text PDFPatients with primary hyperparathyroidism (PHPT) ineligible for surgery require medical management for hypercalcemia and osteoporosis. The aim of this retrospective study was to determine the long-term effects of evocalcet on serum corrected calcium (cCa) levels and bone mineral density (BMD) in PHPT. The study included 26 patients with PHPT and hypercalcemia treated with evocalcet (7 switched from cinacalcet) for at least 24 months.
View Article and Find Full Text PDF: While sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use of the SGLT2 inhibitor ipragliflozin confers kidney protection in individuals with T1D, we retrospectively analyzed data from a real-world cohort examined at 25 centers in Japan. : We enrolled 359 subjects aged 20-74 years with T1D (IPRA group: 159 ipragliflozin users; control [CTRL] group: 200 non-users).
View Article and Find Full Text PDFBackground: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are important for treating patients with preserved left ventricular (LV) ejection fraction (LVEF). Several studies have assessed the effects of SGLT2 inhibitors on LV diastolic function, with conflicting results. In this sub-analysis of the Program of Ipragliflozin for Endothelial Dysfunction in Chronic Kidney Disease and Type 2 Diabetes (PROCEED) trial-including patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)-we examined the effect of ipragliflozin compared with non-SGLT2 inhibitor standard therapy (control) on changes in the maximum early diastolic velocity to average early diastolic peak velocity (E/e') ratio (an index of LV diastolic function) via echocardiography.
View Article and Find Full Text PDFBackground: Ectopic fat is also formed in muscles as well as the liver, where adipose-derived mesenchymal stem cells (ADSCs) promote adipogenesis. On the other hand, after muscle injury, muscle satellite cells (SCs) contribute to muscle repair through myodifferentiation. Human ADSCs are multipotent stem cells, but it remains unclear whether they are involved in myoblast differentiation.
View Article and Find Full Text PDFAims: This study determined the association of the glycaemia risk index (GRI), a novel comprehensive metric derived from continuous glucose monitoring (CGM), and atherosclerosis in patients with type 2 diabetes (T2DM).
Methods: We evaluated the relationship between GRI and intima-media thickness (IMT), gray-scale median (GSM), tissue characteristics of the carotid artery wall, and brachial-ankle pulse wave velocity (baPWV), using baseline data from a multicenter prospective cohort study of 1000 Japanese patients with T2DM free of cardiovascular disease (CVD).
Results: The study subjects were 999 patients (age: 64.
Background: De novo chronic myeloid leukemia in blastic phase (CML-BP) showing lymphoid immunophenotype mimics Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Although upfront allogeneic hematopoietic cell transplantation (HCT) is considered in both diseases, it is not yet clear whether the transplant outcomes are also similar.
Methods: Using a registry database, the transplant outcomes between de novo CML-BP and Ph-positive ALL in negative-minimal residual disease (MRD), positive MRD, and nonremission cohorts were compared, respectively.
Gilteritinib is a tyrosine kinase inhibitor (TKI) that treats acute myeloid leukemia (AML) by inhibiting FMS-like tyrosine kinase 3 (FLT3). This is a report on hypopituitarism induced by gilteritinib and its resolution following withdrawal. A 54-year-old woman was treated with gilteritinib for AML.
View Article and Find Full Text PDFArticle Synopsis
- Bendamustine (BDM) has shown effectiveness in treating certain lymphomas with minimal side effects, but its impact on ATL had not been studied.
- This research demonstrated that combining BDM with tucidinostat enhances cytotoxic effects and could potentially extend survival in patients with relapsed or refractory ATL, warranting further clinical investigation.
Article Synopsis
- Surgery is the primary treatment for insulinoma, and correctly locating the tumor is vital for effective management.
- The selective arterial calcium injection (SACI) test is a key method for localizing insulinomas, but sometimes it may not provide clear results.
- In a case where the conventional SACI was ineffective, a hyperselective SACI test successfully identified the tumor's location, enabling a targeted surgical resection while preserving vital parts of the pancreas.
Article Synopsis
- - A study was conducted to assess whether changing antibiotics or adding glycopeptide antibiotics helps patients with persistent febrile neutropenia (FN) after autologous hematopoietic cell transplantation (auto-HCT) recover faster.
- - The analysis involved 208 patients, and it found no significant improvement in recovery time for those who switched antibiotics; in fact, adding glycopeptides was linked to a longer recovery time.
- - The conclusion suggested that routine changes in antibiotics might not be beneficial for treating persistent FN after auto-HCT, indicating a need to reconsider common antibiotic management practices in such cases.
Article Synopsis
- Ruxolitinib treatment has potential benefits for quality of life and survival in patients with primary myelofibrosis (PMF), leading to questions about the best timing for allogeneic hematopoietic cell transplantation (HCT) in this context.
- A Markov model analysis revealed that delayed HCT after ruxolitinib failure generally offers better outcomes in terms of life expectancy and quality-adjusted life years (QALYs) compared to immediate HCT.
- The study found that delayed HCT was particularly beneficial for patients aged 60 and older, while it was equivalent for those younger than 60, suggesting a more strategic approach to transplantation timing may enhance patient outcomes.
Article Synopsis
- Impaired insulin secretion is linked to increased blood sugar variability in type 2 diabetes (T2DM), but its effect on time in range (TIR) was previously unreported.
- A study involving 330 T2DM patients found a significant correlation between insulin secretory capacity (measured by the S-CPR index) and TIR; patients with higher S-CPR index levels had better time in range blood sugar control.
- The study suggests that the S-CPR index could serve as a useful biomarker for assessing insulin secretion and its relationship with maintaining optimal glucose levels in T2DM patients.
Article Synopsis
- The study investigates how sodium-glucose cotransporter 2 (SGLT2) inhibitors, specifically empagliflozin, affect blood pressure in Japanese patients with type 2 diabetes who are at high risk for cardiovascular disease.
- In a post-hoc analysis from the EMBLEM trial, researchers compared 105 participants taking empagliflozin versus a placebo over 24 weeks and measured changes in blood pressure.
- Results showed that empagliflozin significantly reduced systolic and diastolic blood pressure, with reductions in mean arterial pressure, and this effect was consistent across various clinical backgrounds and antihypertensive medication usage.
We report two rare cases of painful thyroiditis approximately 100 days after unrelated cord blood transplantation (CBT), which progressed to hypothyroidism. Patient one, a 45-year-old woman, developed goiter, tenderness, and thyrotoxicity on day 100 after CBT for relapsed acute lymphocytic leukemia. Scintigraphy suggested destructive thyroiditis; symptoms improved with one-month beta-blocker and prednisolone treatment.
View Article and Find Full Text PDFArticle Synopsis
- * While there's evidence of a correlation between vitamin D deficiency and diabetes, it's unclear if the lack of vitamin D directly causes diabetes.
- * Recent studies indicate that vitamin D supplementation might be effective in preventing both type 1 and type 2 diabetes, although earlier randomized trials showed mixed results.
The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
J Bone Miner Metab
March 2024
Article Synopsis
- Synthetic glucocorticoids (GCs) are widely used for treating autoimmune diseases but can lead to glucocorticoid-induced osteoporosis (GIOP), which significantly impacts patient quality of life and leads to fractures in many patients.
- In 2014, the Japanese Society for Bone and Mineral Research established treatment guidelines for managing GIOP, using risk factors like age and bone density to determine appropriate therapy for patients on GC treatment for over three months.
- The updated 2023 guidelines recommend starting osteoporosis medications, such as bisphosphonates and anti-RANKL antibodies, alongside GC therapy for high-risk patients to help prevent fractures.
Article Synopsis
- A study investigated whether treatment with active vitamin D (eldecalcitol) could lower the risk of developing sarcopenia in adults with prediabetes, given previous observational findings suggesting a connection between vitamin D levels and sarcopenia.
- The research was a randomized, double-blind, placebo-controlled trial involving 1,094 participants across 32 sites in Japan, measuring sarcopenia incidence over three years.
- Results showed that those treated with eldecalcitol had a significantly lower incidence of sarcopenia compared to the placebo group, with no notable difference in adverse events, indicating potential benefits of vitamin D treatment for muscle health.
Article Synopsis
- Accurate differentiation between donor-derived post-transplant lymphoproliferative disorder (PTLD) and relapsed recipient-derived lymphoproliferative disorder (LPD) is essential for effective treatment post-hematopoietic stem cell transplantation (HSCT).
- Traditional diagnostic methods often fall short, especially in cases involving Epstein-Barr virus (EBV)-positive LPDs with low tumor cell counts.
- The newly developed method utilizes sex chromosome fluorescence in situ hybridization and other techniques on a single tissue section, successfully enabling accurate diagnosis of difficult cases and preserving histological structure.
Higher rate of nonrelapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graft sources, a UCBT-specific NRM risk assessment system is required. Thus, in this study, we sought to develop a UCBT-specific NRM Risk Assessment (CoBRA) score.
View Article and Find Full Text PDFArticle Synopsis
- This study compared the effects of two diabetes medications: mitiglinide/voglibose and glimepiride, on blood sugar levels and blood vessel health in type 2 diabetes patients.
- It was conducted as a multicenter, open-label, randomized crossover trial involving 30 hospitalized patients, measuring outcomes like blood glucose variability and vascular function over a 5-day treatment period for each drug.
- Results showed that while both medications had similar effects on vascular function, mitiglinide/voglibose significantly reduced blood sugar fluctuations and time spent in extreme glucose ranges compared to glimepiride.
Article Synopsis
- The study aimed to investigate how biological and targeted synthetic DMARDs (b/tsDMARDs) affect bone metabolism in patients with rheumatoid arthritis (RA) over a 52-week period.
- A total of 1164 RA patients were monitored, revealing that those not on anti-osteoporotic agents (anti-OP) experienced a significant decline in bone mineral density (BMD) despite improved disease activity, while those on anti-OP maintained stable BMD.
- The findings suggest that osteoporosis may worsen in RA patients not receiving anti-OP during b/tsDMARD treatment, indicating the need for regular BMD monitoring for early osteoporosis management.
Objective: Currently, the most frequently prescribed once weekly glucagon-like peptide-1 receptor agonists (GLP-1RA) in Japan are dulaglutide (DG) and semaglutide (SG). However, little is known about the differences between these two compounds in clinical practice in Japan. This study compared the efficacy and safety of DG and SG using professional CGM in 12 patients attending our outpatient with poorly controlled type 2 diabetes mellitus (T2DM) while using GLP-1RA.
View Article and Find Full Text PDFArticle Synopsis
- * 600 participants underwent CGM and carotid artery imaging at the start and after 104 weeks to assess changes in atherosclerosis, primarily measuring intima-media thickness (IMT) and grey-scale median (GSM).
- * Results showed slight increases in mean IMT and thickened-lesion GSM over the study period, with significant associations found between baseline CGM-derived metrics (time in range and coefficient of variation) and changes in mean GSM over time.